Tags

Type your tag names separated by a space and hit enter

Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.
Mol Diagn Ther. 2020 Jul 01 [Online ahead of print]MD

Abstract

The novel coronavirus infection has spread worldwide, causing a wide spectrum of clinical manifestations. Most patients develop moderate clinical illness, but a substantial number will experience severe pneumonia, which may rapidly progress to acute respiratory distress syndrome and multiple organ failure. In this population, soluble urokinase plasminogen activator receptor (suPAR) could serve as a quick triage test and independent marker of clinical severity, hospital and intensive care unit admission, complications, and mortality.

Authors+Show Affiliations

Department of Anesthesiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larisa, Greece. thanoschalkias@yahoo.gr.Department of Cardiology, General Hospital of Paphos, Paphos, Cyprus.Department of Anesthesiology, Tzaneio General Hospital, Piraeus, Greece.School of Medicine, European University Cyprus, Nicosia, Cyprus.First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Department of Emergency Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larisa, Greece.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32613288

Citation

Chalkias, Athanasios, et al. "Soluble Urokinase Plasminogen Activator Receptor: a Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients." Molecular Diagnosis & Therapy, 2020.
Chalkias A, Mouzarou A, Samara E, et al. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Mol Diagn Ther. 2020.
Chalkias, A., Mouzarou, A., Samara, E., Xanthos, T., Ischaki, E., & Pantazopoulos, I. (2020). Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-020-00481-8
Chalkias A, et al. Soluble Urokinase Plasminogen Activator Receptor: a Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Mol Diagn Ther. 2020 Jul 1; PubMed PMID: 32613288.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. AU - Chalkias,Athanasios, AU - Mouzarou,Angeliki, AU - Samara,Evangelia, AU - Xanthos,Theodoros, AU - Ischaki,Eleni, AU - Pantazopoulos,Ioannis, Y1 - 2020/07/01/ PY - 2020/7/3/entrez PY - 2020/7/3/pubmed PY - 2020/7/3/medline JF - Molecular diagnosis & therapy JO - Mol Diagn Ther N2 - The novel coronavirus infection has spread worldwide, causing a wide spectrum of clinical manifestations. Most patients develop moderate clinical illness, but a substantial number will experience severe pneumonia, which may rapidly progress to acute respiratory distress syndrome and multiple organ failure. In this population, soluble urokinase plasminogen activator receptor (suPAR) could serve as a quick triage test and independent marker of clinical severity, hospital and intensive care unit admission, complications, and mortality. SN - 1179-2000 UR - https://www.unboundmedicine.com/medline/citation/32613288/Soluble_Urokinase_Plasminogen_Activator_Receptor:_A_Biomarker_for_Predicting_Complications_and_Critical_Care_Admission_of_COVID-19_Patients L2 - https://dx.doi.org/10.1007/s40291-020-00481-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.